Drug Profile
Ascorbic acid/menadione
Alternative Names: Apatone; Apatone-BLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Summa Health System
- Developer IC-MedTech; Summa Health System
- Class Antineoplastics; Naphthoquinones; Small molecules; Vitamins
- Mechanism of Action Antioxidants; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Joint disorders
- Phase I/II Prostate cancer
- No development reported Polycystic kidney disease
- Discontinued Wounds
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Polycystic-kidney-disease in USA (PO)
- 28 Jan 2016 Ascorbic acid/menadione is available for licensing -http://www.ic-medtech.com/partnerships_licensing.html
- 10 Aug 2015 Development of ascorbic acid/menadione is ongoing in USA